<i>FGFR2</i> fusions as novel oncogenic drivers in gastrointestinal stromal tumors: Two case reports and review of literature
Our findings provided preliminary evidence that novel <i>FGFR2</i> fusions might act as primary oncogenic drivers in a rare subset of <i>KIT</i>/<i>PDGFRA</i> wild-type GISTs. These cases highlight the importance for comprehensive genomic profiling and suggest that fibroblast growth factor receptor-targeted inhibitors could be a potential therapeutic strategy for advanced or imatinib-resistant diseases, warranting further investigation in larger cohorts.
Authors
- Jiren Yu (ORCID: https://orcid.org/0000-0002-7904-107X)
- Yanyun Hong
- Qing Zhang (ORCID: https://orcid.org/0000-0002-3549-8780)
- Xiaodong Wang (ORCID: https://orcid.org/0000-0003-1215-6953)
- Weili Yang (ORCID: https://orcid.org/0000-0003-3646-7772)
- Xiaosun Liu (ORCID: https://orcid.org/0000-0003-3365-2155)
- Chunhui Shou
Institutions
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.4251/wjgo.v17.i11.113262
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00